AI assistant
ARIX BIOSCIENCE PLC — Director's Dealing 2017
May 9, 2017
4968_dirs_2017-05-09_f68872bf-1fff-4f3e-8b02-d6fd166fd3ab.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5310E
Arix Bioscience Plc
09 May 2017
Director share purchases
LONDON, 09 May 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that several key members of its leadership team have purchased shares in the Company.
Joe Anderson, Chief Executive Officer of Arix Bioscience, purchased 21,532 ordinary shares in the Company at a price of 202.39p per Ordinary Share.
Jon Peacock, Chairman of Arix Bioscience, purchased 11,484 ordinary shares in the Company at a price of 202.39p per Ordinary Share.
James Rawlingson, Chief Financial Officer of Arix Bioscience, purchased 11,484 ordinary shares in the Company at a price of 202.39p per Ordinary Share.
PDMR Dealing Notifications
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Joseph Anderson | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 202.39 pence | 21,532 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 08 May 2017 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Jonathan Peacock | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chairman | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 202.39 pence | 11,484 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 08 May 2017 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | James Hedley Rawlingson | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Financial Officer | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 202.39 pence | 11,484 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 08 May 2017 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSSWESAFWSEII